New Success Data on Lucentis
Newly released results from the
Lucentis studies show just how successful the
macular degeneration drug is.
 The
latest, two-year information from the
Lucentis
studies revealed positive new findings about the
success of the drug.
The study demonstrated that the patients who's
visual acuity improved from Lucentis therapy,
maintained their improved vision at year two.
Since age-related macular degeneration is an
ongoing, progressive eye disease, the news that
vision improvements from Lucentis last at least two
years is exciting.
The study also showed that 90% of patients treated
with 0.3mg and 0.5mg Lucentis either maintained or
improved vision and up to 41% of Lucentis patients
had improved vision.
Related information:
New Lucentis v. Stroke Information
Interim Lucentis study data
showed that, at six months into the study, Lucentis
use in stroke patients may lead to an increased risk
of stroke.
However, once the final study was complete, results
showed that there was no associated risk of
stroke in patients getting Lucentis treatment.
ref: Review of Ophthalmology |
